Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap

July 16, 2025

Government price negotiations under the Inflation Reduction Act may hinder biosimilar development, impacting drug costs and patient access to affordable therapies.

FDA Approves Kirsty as First Interchangeable Insulin Aspart Biosimilar

July 15, 2025

White Paper Offers Tips for Sustaining Biosimilar Progress, Avoiding a Market Void

July 15, 2025

BioRationality: How the FDA Can Bypass Congress to Change Biosimilar Guidance

July 14, 2025

Balancing Cost Savings With Clinical Practice for Multiple Myeloma Biosimilars: Tyler Sandahl, PharmD

July 14, 2025

Biosimilars Rheumatology Roundup for April 2023—Podcast Edition

April 30th 2023

By Skylar Jeremias

Podcast

On this episode of Not So Different, we recap some of the main news in April regarding biosimilars used to treat rheumatic conditions, including some progressions and some setbacks as well as research on nonmedical switching from originators to biosimilars.

Biosimilars Rheumatology Roundup: April 2023

April 29th 2023

By Skylar Jeremias

Article

In April, biosimilars to treat rheumatic conditions had some progress, as well as some setbacks, and research showed that switching from originators to biosimilars is safe and effective but warned about the nocebo effect.

Biosimilar Ranibizumab Displays Comparable Safety, Efficacy to Lucentis

April 28th 2023

By Justina Petrullo

Article

Biosimilar ranibizumab showed similar efficacy and safety in a recent study of the eyes of Indian patients with neovascular age-related macular degeneration.

The Top 5 Biosimilar Articles for the Week of April 24

April 28th 2023

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of April 24, 2023.

Study on Nonmedical Switching for Adalimumab Biosimilars Warns About Nocebo Effect

April 27th 2023

By Skylar Jeremias

Article

Nonmedical switches from Humira (reference adalimumab) to a biosimilar or an adalimumab biosimilar to another biosimilar resulted in nocebo effect responses, suggesting that more communication between providers and patients is needed, according to a real-world analysis.

Biosimilars Check In: Vegzelma Launch, BLA Acceptances, China Approval

April 26th 2023

By Skylar Jeremias

Article

Over the past week, Vegzelma, a bevacizumab biosimilar, launched in the United States; 2 biologics license applications (BLAs) for biosimilars were accepted for review by the FDA; and China’s regulatory agency approved a denosumab biosimilar.

Senators Introduce Bill to Establish Insulin Cap for Commercial Plans

April 25th 2023

By Skylar Jeremias

Article

Two US senators introduced a bipartisan bill to extend the $35 out-of-pocket cap for insulin products, established by the Inflation Reduction Act for Medicare plans, to the commercial sector.

Price Variation in Economic Evaluations of Infliximab Could Influence Biosimilar Access

April 24th 2023

By Justina Petrullo

Article

A recent systematic review looked at the impact of different prices for infliximab in inflammatory bowel disease and the willingness-to-pay threshold around the world.

Dr Andre Harvin Explains His Excitement for Neulasta Onpro Biosimilars

April 23rd 2023

By Skylar Jeremias

Video

Andre Harvin, PharmD, executive director of pharmacy and oncology services at Cone Health, expressed staunch belief that biosimilars referencing Neulasta Onpro, the on-body injector version of reference pegfilgrastim, are one of the most exciting things coming to the supportive cancer care space.

SB11 Demonstrates Biosimilarity to Lucentis in Long-term Study in nAMD

April 22nd 2023

By Deana Ferreri, PhD

Article

A long-term follow-up of a phase 3 study comparing ranibizumab biosimilar SB11 to the reference product (Lucentis) in neovascular age-related macular degeneration (nAMD) found the similarity in efficacy end points reported early on was maintained through 52 weeks.